Dicerna Pharmaceuticals (DRNA:NASDAQ) Annual Reports & Investor Relations Material

Overview

Dicerna Pharmaceuticals is a US-based biopharmaceutical company that specializes in developing treatments for liver diseases and cancers using their proprietary RNA interference technology platform. Its main development program is DCR-PH1, which aims to treat primary hyperoxaluria type 1 (PH1) and other rare inherited diseases that involve genes expressed in the liver.

Annual Reports

Frequently Asked Questions

What is Dicerna Pharmaceuticals's ticker?

Dicerna Pharmaceuticals's ticker is DRNA

What exchange is Dicerna Pharmaceuticals traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Dicerna Pharmaceuticals's headquarters?

They are based in Cambridge, Massachusetts

How many employees does Dicerna Pharmaceuticals have?

There are 11-50 employees working at Dicerna Pharmaceuticals

What is Dicerna Pharmaceuticals's website?

It is dicerna.com

What type of sector is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals is in the Healthcare sector

What type of industry is Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals is in the Biotechnology industry

Who are Dicerna Pharmaceuticals's peers and competitors?

The following five companies are Dicerna Pharmaceuticals's industry peers:

- Optical Cable

- American Virtual Cloud Technologies, Inc.

- Imv

- Vitae

- Rhythm Pharmaceuticals